甘李藥業(603087.SH):門冬胰島素獲得印度尼西亞原料藥註冊批件
格隆匯1月7日丨甘李藥業(603087.SH)公佈,近日,公司收到印度尼西亞藥監局(BPOM)核准簽發的門冬胰島素原料藥註冊批件(批件號:RG.01.01.32.322.12.20.01214/H)。
門冬胰島素原料藥可用於灌裝生產門冬胰島素注射液,門冬胰島素注射液屬於速效胰島素類似物產品,又稱餐時胰島素,注射後能快速被吸收,可在餐前或餐後即刻注射,給患者使用帶來便利。與可溶性人胰島素相比,門冬胰島素經皮下注射後起效更快,作用持續時間更短,更符合人體進餐後生理性胰島素分泌模式,緊鄰餐時注射,應用更加便捷,可明顯改善餐後血糖,因此門冬胰島素注射液成為糖尿病治療中尤為重要的餐時胰島素。
截至2020年9月30日,公司在門冬胰島素研發項目上已累計投入約1.03億元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.